These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18729547)

  • 1. Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects.
    Chan AL; Chien YW; Jin Lin S
    Drugs Aging; 2008; 25(9):761-75. PubMed ID: 18729547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal treatment options for neurological disorders: impact on the elderly.
    Priano L; Gasco MR; Mauro A
    Drugs Aging; 2006; 23(5):357-75. PubMed ID: 16823990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world evaluation of compliance and preference in Alzheimer's disease treatment.
    Pai MC; Aref H; Bassil N; Kandiah N; Lee JH; Srinivasan AV; diTommaso S; Yuksel O
    Clin Interv Aging; 2015; 10():1779-87. PubMed ID: 26622172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease.
    Winblad B; Machado JC
    Expert Opin Drug Deliv; 2008 Dec; 5(12):1377-86. PubMed ID: 19040398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal Drug Delivery Systems and their Potential in Alzheimer's Disease Management.
    Siafaka PI; Bülbül EÖ; Mutlu G; Okur ME; Karantas ID; Okur NÜ
    CNS Neurol Disord Drug Targets; 2020; 19(5):360-373. PubMed ID: 32552655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Updates in Transdermal Therapeutic Systems and Their Role in Neurological Disorders.
    Yadav N; Mittal A; Ali J; Sahoo J
    Curr Protein Pept Sci; 2021; 22(6):458-469. PubMed ID: 33183199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
    Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT
    Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.
    Amanatkar HR; Grossberg GT
    Expert Rev Neurother; 2014 Oct; 14(10):1119-25. PubMed ID: 25201245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.
    Yang LP; Keating GM
    CNS Drugs; 2007; 21(11):957-65. PubMed ID: 17927299
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
    Darreh-Shori T; Jelic V
    Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
    Cagnin A; Cester A; Costa B; Ermani M; Gabelli C; Gambina G;
    Neurol Sci; 2015 Mar; 36(3):457-63. PubMed ID: 25394739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.
    Nieto RA; Deardorff WJ; Grossberg GT
    Expert Opin Pharmacother; 2016; 17(6):861-70. PubMed ID: 26918774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
    Reñé R; Ricart J; Hernández B;
    Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].
    Wouters CJ; Dautzenberg L; Thissen A; Dautzenberg PL
    Tijdschr Gerontol Geriatr; 2010 Jun; 41(3):146-50. PubMed ID: 20593742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Alzheimer's disease. New developments.
    Giacobini E; Michel JP
    Ann Med Interne (Paris); 1998 Jun; 149(4):231-7. PubMed ID: 11490551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current advances in transdermal delivery of drugs for Alzheimer's disease.
    Nguyen TT; Giau VV; Vo TK
    Indian J Pharmacol; 2017; 49(2):145-154. PubMed ID: 28706327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.